Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker

• Published in: Journal of translational medicine 2012-07, Vol.10 (1), p.140-140, Article 140
• Main Authors: Vassiliadis, Efstathios, Rasmussen, Lars M, Byrjalsen, Inger, Larsen, Dorthe Vang, Chaturvedi, Rajiv, Hosbond, Susanne, Saabye, Lotte, Diederichsen, Axel C P, Genovese, Federica, Duffin, Kevin L, Zheng, Qinlong, Chen, Xiaoliang, Leeming, Diana J, Christiansen, Claus, Karsdal, Morten A
• Format: Article
• Language: English
• Subjects: Acute myocardial infarction; Biomarker; Biomarkers; Biomarkers - blood; Cardiovascular; Cardiovascular disease; Cardiovascular Diseases - metabolism; Cardiovascular Diseases - pathology; Case-Control Studies; Cloning; Connectin; CVD; Enzyme-Linked Immunosorbent Assay; Heart attack; Heart attacks; Humans; Hypotheses; Immunoassay; Mass spectrometry; Matrix Metalloproteinase 12 - metabolism; Middle Aged; MMP-12; Molecular weight; Muscle Proteins - metabolism; Muscles; Neoepitope; Pathology; Peptides; Protein Kinases - metabolism; Proteins; Proteolysis; ROC Curve; Statistical analysis; Titin
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/1479-5876-10-140

Titin is a muscle-specific protein found in cardiac and skeletal muscles which is responsible for restoring passive tension. Levels and functioning of titin have been shown to be affected by cardiac damage. Due to the inherent difficulty of measuring titin levels in vivo in a clinical setting, we aimed to develop an assay that could reliably measure fragments of degraded titin in serum and potentially be used in the assessment of cardiac muscle damage. A competitive ELISA was developed to specifically measure levels of the titin sequence 12670' NVTVEARLIK 12679', derived by the degradation of titin by matrix metalloproteinase (MMP)-12. Serum samples from 90 individuals were divided into 3 equally sized groups. One group had been diagnosed with acute myocardial infarction (AMI) while the remaining two were asymptomatic individuals either with CT-scan signs of coronary calcium (CT-plusCa) or without coronary calcium (CT-noCa). Mean geometric levels of the titin fragment in the CT-noCa group were 506.5 ng/ml (± 43.88). The CT-plusCa group showed 50.6% higher levels of the marker [763 ng/ml (± 90.14)] (P < 0.05). AMI patients showed 56.3% higher levels [792 ng/ml (± 149)] (P < 0.05). The titin-12670 fragment is present in both individuals with undiagnosed and diagnosed CVD. The statistically significant increase in level of the marker in the AMI group is indicative that this neoepitope biomarker may be a useful serological marker in AMI.